Levodopa/Carbidopa/Entacapone Rivopharm

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Rivopharm, is an antiparkinson agent presented as a tablet for oral administration. It combines three pharmacological components to increase central dopamine levels and is indicated for the treatment of Parkinson's disease in adult patients. It is formulated to be taken multiple times daily, allowing flexible dosing adjusted by the prescribing physician.

GNH USA supplies Levodopa/Carbidopa/Entacapone Rivopharm as a licensed, Good Distribution Practice‑compliant product, providing reliable international sourcing for hospitals, pharmacies and clinical centres worldwide, with support for regulatory documentation and logistics, ensuring product integrity throughout the supply chain.

Levodopa/Carbidopa/Entacapone is used within the Parkinson's disease therapeutic pathway to enhance dopaminergic therapy.

- Parkinson's disease (motor fluctuations): Reduces off‑time and improves motor symptom control when combined with levodopa. - Parkinson's disease (early‑stage adjunct therapy): Provides symptomatic benefit as part of initial combination treatment. - Parkinson's disease (advanced disease with wearing‑off): Extends levodopa effect and stabilizes dopamine levels.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Dyskinesia (involuntary movements) - Orthostatic hypotension - Dizziness or light‑headedness - Insomnia

Serious or Rare Side Effects: - Severe hypotension or syncope - Neuroleptic malignant syndrome - Severe allergic reactions (rash, angioedema, anaphylaxis) - Hyperpyrexia - Severe depression or suicidal thoughts - Hallucinations or psychosis

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several safety measures.

- Monitor blood pressure: watch for orthostatic changes, especially at therapy initiation. - Assess for dyskinesia: adjust dosage if excessive involuntary movements develop. - Review psychiatric status: monitor for depression, hallucinations, or suicidal ideation. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal effects. - Use with caution in renal or hepatic impairment: dose may require adjustment based on organ function. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Levodopa/Carbidopa/Entacapone interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic agents: may diminish levodopa efficacy. - High‑dose pyridoxine (vitamin B6): interferes with carbidopa activity.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: additive hypotensive effect. - SSRIs or SNRIs: potential for serotonin syndrome. - Iron or calcium supplements: reduce levodopa absorption if taken concurrently.